Tags
Blog

'MS Center' posts

Multiple Sclerosis Center Celebrates First Anniversary

One year ago today, the first patients visited the brand new Multiple Sclerosis (MS) Center at Swedish Neuroscience Institute. The 11,700-square-foot facility was designed around the patient experience as part of the MS Center’s commitment to treating the whole person and addressing each patient’s individual emotional, psychological, social and physical needs in a supportive environment.

Since we opened our doors on April 9, 2012, we’ve hit a few new milestones:

  • More than 5,400 total patients, including 620 new faces, from around the world received care from our comprehensive treatment team in the last 12 months.

  • We welcomed three new providers: neurologist Peiqing Qian, M.D.; physical therapist Kim Kobata, PT; and neuro-psychiatrist Lina Fine, M.D., M.Phil.

  • We completed the Pigott Terrace. The 1,500-square-foot outdoor therapy terrace includes a one-of-a-kind system that enables patients to ...

Staying productive in the workplace with Multiple Sclerosis (MS)

"But you're so young!" is a reaction a many people with multiple sclerosis (MS) may hear when they talk about their diagnosis. There is a common misconception that MS is diagnosed older or appear much more disabled. However, most people are diagnosed between the ages of 20 and 40, smack in the prime of her or his life and career.

MS symptoms may affect a person's ability to work and participate in an educational program more or less depending on the course of their disease. Many people wonder if they can keep working or they quit because of their MS limitations, causing financial stress.

There is a place in the workplace for people with MS and there are options to support you. Shaheen Virani is a Certified Rehabilitation Counselor at the MS Center at Swedish. A vocational counselor can help people living with MS navigate their employment options, whether it is to continue working, make a career change or apply for disability.

Vocational services at the MS Center are free and can often be coordinated with other appointments on the same day. A counselor can support people with MS in many ways, including:

New medication for MS, Tecfidera (BG-12), Approved by FDA

On March 27, the U.S. Food and Drug Administration approved the newest treatment in the increasing number of disease modifying therapies (DMTs) available to treat multiple sclerosis. Tecfidera (BG-12) is an oral capsule to treat adults with relapsing forms of MS. Research participants at the MS Center at Swedish participated in clinical trials for Tecfidera.

 

The trials reported that people taking Tecfidera had fewer relapses and less frequent worsening of disability compared to people taking a placebo. There were also fewer and less-severe side effects with Tecfidera than other treatments.

 

The studies found that ...

Swedish Presents Research at 2013 AAN Annual Meeting

Neurologists and neuroscience professionals this week from around the world gathered at the American Academy of Neurology (AAN) 65th Annual Meeting in San Diego. The Multiple Sclerosis Center at Swedish Neuroscience Institute was pleased to co-author a few research trials presented at the meeting:

 

Teriflunomide and pregnancy

Dr. Lily Jung-Henson speaking at the AAN 65th Annual MeetingDr. Lily Jung-Henson, neurologist and Chief of Staff at Swedish Issaquah, spoke on behalf of a team of researchers about teriflunomide and a report on the safety of women who became pregnant on the medication. Teriflunomide is a once-daily, oral disease-modifying therapy (DMT) recently approved in the United States to treat relapsing multiple sclerosis. Clinical trials for teriflunomide took place among the many research studies for new treatments Swedish Neuroscience Institute offers patients with multiple sclerosis. (Read the full abstract here.)

Subset of a trial looking at endurance effects of Dalfampridine (AMPYRA®)

Dr. Angeli Mayadev, physical medicine and rehabilitation specialist at the MS Center, participated in this study of a medication to improve walking speed in people with MS. Dalfampridine -ER 10 mg twice daily significantly improved 6-minute walking distance compared to placebo. Dalfampridine 5 mg twice daily did not improve distance compared to placebo. Researchers also found that ....

MS Research Update: Pulse therapy for breakthrough multiple sclerosis

A small pilot study from the University of Southern California suggests a pulse adrenocorticotropic hormone (ACTH) therapy could be effective in patients with breakthrough multiple sclerosis attacks while on beta-interferon. “Breakthrough” attacks that occur after starting a disease modifying therapy (DMT).

 

The study compared the safety and benefits of monthly pulse ACTH to monthly methylprednisone (MP) pulse in patients on beta-interferon. Over 15 months, researchers found that those treated with ACTH had fewer relapses and fewer psychiatric side effects. ACTH gel is currently used to treat MS relapses, but researchers note it may be able to alter the body’s immune responses beyond producing steroids.

 

As I discussed with the Medscape reporter, Megan Brooks, last week, the results of this study are ....

Seahawks’ Blitz and Dr. Bowen Demystify MS

Dr. James Bowen appeared today with Ryan Asdourian, “the man behind the bird” and Seahawks’ mascot Blitz, on the Seattle talk show New Day Northwest to shed some light on common misconceptions about multiple sclerosis (MS).

 

Host Margaret Larson asked Dr. Bowen about myths about MS as part of the program to promote this year’s Walk MS events in Seattle. Ryan Asdourian is proof of the full life many people lead with MS, rallying fans at Seahawks games and raising MS awareness as an active advocate for the National Multiple Sclerosis Society.

 

You can check out the video from KING5 TV’s website below. Find out more about how to join or donate to the Swedish S’myelin Strider’s Walk MS team at www.swedish.org/MS.

MS Research Update: Salt and Multiple Sclerosis

Increased dietary salt was reported to increase the immune attack on myelin in three studies this week. All three were published in the journal Nature.

  1. A study by Kleinewietfeld, et al, looked at TH17 cells, which is a type of lymphocyte that is highly inflammatory and that causes substantial tissue damage. These cells were grown in cultures in the lab. Some had normal and others high salt levels in their cultures. Those grown in a high salt environment had increased markers for inflammation. This seemed to be due to activation of one particular set of chemical signals in the cell, called the p38/MAPK pathway. They also looked at mice with an MS-like disease called experimental allergic encephalomyelitis (EAE). Mice fed a high salt diet had worse EAE than those fed a normal diet.
  2. A study by Wu, et al, also looked at TH17 cells. An analysis was done on genes associated with activation of TH17 cells, and SGK1 was identified as an important protein in this process. The SGK1 pathway was found to be more active if cells were cultured in a high salt environment. This was then studied in mice with EAE. Mice fed a high salt diet had more severe EAE. Blocking the SGK1 pathway seemed to reverse the effect of the high salt diet on the EAE.
  3. A study by Yosef, et al, also looked a the genes associated with activation of TH17 cells. They identified 22 sets of related genes that increased TH17 cell activity and 5 that decreased activity.

TH17 cells are highly inflammatory and likely contribute to the severe damage done to tissues in a number of diseases. Their precise role in MS is not fully understood, but it is believed that ...

Results 50-56 of 59